A Study Investigating Peripheral Cryoneurolysis in Adults With Chronic Migraine

Prior treatment

• Subject is unable to differentiate migraine from other concomitant headaches.
• Subject has had a change in type, dosage or dose frequency of preventive headache medications during the baseline period.
• Ongoing abuse of drugs (including narcotics) or alcohol.
• Patients with any kind of conductive implant with contraindication for nerve stimulation.

Other illness

• Subject with secondary headache conditions, with the exception of medication overuse headache.
• Other pain conditions, not intended to be treated in this study, that in the opinion of the investigator could interfere with study procedures, accurate pain reporting, and/or confound evaluation of study endpoints.
• High probability of deterioration due to other medical conditions, that in the opinion of the investigator may confound outcome assessment.
• Other coexisting current medical conditions, including, but not limited to, bleeding diathesis and thrombophilia, that presents excess procedural risk, in the opinion of the investigator.
• Abnormal pain behavior, inappropriate medication use and/or unresolved psychiatric illness, that in the opinion of the investigator are significant enough to impact perception of pain, compliance with intervention and/or ability to evaluate treatment outcome.
• Subject currently has an active abscess or a local infection at the site of intervention based on present symptoms.
• Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving skull or site of intervention that have been active or required treatment in the past 6 months.

Lab values

• Subject that, in the opinion of the investigator, has had no or minimal response to more than 6 adequate trials of prophylactic migraine treatment of the following drug classes:
  • Antidepressant (Amitryptyline, Venlafaxine)
  • Antiepileptic (Topiramate or Valproate)
  • Beta-blocker (Atenol, Metropolol, Propanolol, Timolol)
  • Calcium channel blockers (Flunarizine or Cinnarizine)
  • Drugs acting on the CGRP pathway (Monoclonal antibodies and gepants)
  • Angiotensin-converting enzyme inhibitors (Lisinopril) or angiotensin II receptor blocker (Candesartan)
  • OnabotulinumtoxinA

Other

• More than 4 days of opioid use per month (including codeine and tramadol), and any use of barbiturates
• Anomaly or trauma which renders the planned procedure difficult.
• The subject is not competent to consent

• Participant must be 18 years at the time of signing the informed consent
• Migraine, with or without aura, fulfilling the International Classification of Headache Disorders (ICHD) III criteria 1.3. for chronic migraine at time of inclusion, verified by a neurologist
• History of 8 debilitating headache days per month for at least 3 consecutive months. Debilitating headache is defined as headache causing serious impairment to conduct activities of daily living despite the use of pain-relief drugs with established efficacy at the recommended dose and taken early during the attack; failure of at least two different triptans is required.
• Chronic migraine at least for a period of 1 year prior to inclusion
• Debut of episodic migraine before the age of 50, and chronic migraine before the age of 65.
• The condition is pharmacologically resistant as defined in EHF guidelines as lack of efficacy, lack of tolerability and/or contraindications to at least 3 of the following drug classes
  • Antidepressant (Amitryptyline, Venlafaxine)
  • Antiepileptic (Topiramate or Valproate)
  • Beta-blocker (Atenol, Metropolol, Propanolol, Timolol)
  • Calcium channel blockers (Flunarizine or Cinnarizine)
  • Drugs acting on the CGRP pathway (Monoclonal antibodies and gepants)
  • Angiotensin-converting enzyme inhibitors (Lisinopril) or angiotensin II receptor blocker (Candesartan)
  • OnabotulinumtoxinA
• Subject has had no change in type, dosage or dose frequency of preventive headache medications \< 3 months prior to baseline/screening, or a minimum of 5 half-lives, whichever is longer.
• Subjects has not been treated with steroids orally or injections \>8 weeks (excluding steroid inhalations or topical treatments) prior to baseline and agrees to refrain from steroids orally or injections during baseline and 8 weeks post-intervention.
• Subject agrees to maintain current preventive headache medication regimens (no change in type, frequency, or dose) during baseline and 8 weeks after the intervention.
• Be an appropriate candidate for the study intervention required in this study on the basis of the clinical judgment of the investigator
• Capable of giving signed informed consent as which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.